This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zahger, D. Articles by Cercek, B. Search for Related Content PubMed PubMed Citation Articles by Zahger, D. Articles by Cercek, B.

(Circulation. 1995;92:1269-1273.)
© 1995 American Heart Association, Inc.

Articles

VCL, an Antagonist of the Platelet GP1b Receptor, Markedly Inhibits Platelet Adhesion and Intimal Thickening After Balloon Injury in the Rat

Doron Zahger, MD; Michael C. Fishbein, MD; Leonard I. Garfinkel, PhD; Prediman K. Shah, MD; James S. Forrester, MD; Jan Regnstrom, MD, PhD; Juliana Yano, BS; Bojan Cercek, MD

From the Division of Cardiology, Cedars-Sinai Medical Center and University of California, Los Angeles, and Biotechnology General, Rehovot, Israel (L.I.G.).

Background Arterial injury is immediately followed by platelet adhesion at the site of injury, a process that requires the interaction of subendothelial von Willebrand factor with the platelet GP1b receptor. VCL, a recombinant von Willebrand factor GP1b binding domain, inhibits platelet binding to von Willebrand factor. The aim of this study was to determine whether VCL inhibits platelet adhesion at the site of arterial injury and affects neointimal thickening after injury in rats.

Methods and Results Sprague-Dawley rats were randomized to receive VCL, 4 mg/kg bolus followed by a continuous infusion of 2 mg · kg^-1 · h^-1 for 72 hours, or an identical volume of saline. Balloon injury of the femoral artery was performed 15 minutes after the initial bolus injection of VCL. Scanning electron microscopy performed 1 and 3 days after injury indicated that VCL-treated rats had >80% reduction in the number of platelets adherent to the vessel wall at the site of injury compared with controls (P<.003). Histological examination at day 14 showed that, compared with controls, VCL-treated rats had a 60% reduction in the intima-media ratio (0.21±0.03 versus 0.53±0.06, P=.001) and a reduced luminal area stenosis (12±3% versus 38±10%, P=.04). At 28 days after injury, there was no rebound of neointimal thickening in VCL-treated rats (intima-media ratio, 0.19±0.04; luminal stenosis, 17±5%). The difference between VCL-treated rats and control rats persisted but was attenuated (intima-media ratio, 0.19±0.04 versus 0.28±.0.1, P=.162; luminal stenosis, 17±5% versus 31±5%, P=.058) as neointimal thickening regressed in untreated rats. With the use of proliferating cell nuclear antigen immunohistochemistry on day 3, VCL had no effect on smooth muscle cell (SMC) proliferation.

Conclusions Antagonism of the platelet GP1b receptor by VCL profoundly decreased platelet deposition at the site of balloon injury in the rat femoral artery. This effect was associated with a persistent reduction in neointimal thickening. The lack of effect of VCL on SMC proliferation suggests that the decrease in neointimal thickening may have been mediated through inhibition of SMC migration and/or modulation of the extracellular matrix.

Key Words: VCL • balloon • von Willebrand factor • muscle, smooth • platelets

This article has been cited by other articles:

				J. Liu, M. E. Fitzgerald, M. C. Berndt, C. W. Jackson, and T. K. Gartner Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo Blood, October 15, 2006; 108(8): 2596 - 2603. [Abstract] [Full Text] [PDF]

				H. V. Anderson, J. McNatt, F. J. Clubb, M. Herman, J.-P. Maffrand, F. DeClerck, C. Ahn, L. M. Buja, and J. T. Willerson Platelet Inhibition Reduces Cyclic Flow Variations and Neointimal Proliferation in Normal and Hypercholesterolemic-Atherosclerotic Canine Coronary Arteries Circulation, November 6, 2001; 104(19): 2331 - 2337. [Abstract] [Full Text] [PDF]

				S. Kageyama, H. Yamamoto, and R. Yoshimoto Anti-Human von Willebrand Factor Monoclonal Antibody AJvW-2 Prevents Thrombus Deposition and Neointima Formation After Balloon Injury in Guinea Pigs Arterioscler Thromb Vasc Biol, October 1, 2000; 20(10): 2303 - 2308. [Abstract] [Full Text] [PDF]

				N. Cauwenberghs, M. Meiring, S. Vauterin, V. van Wyk, S. Lamprecht, J. P. Roodt, L. Novak, J. Harsfalvi, H. Deckmyn, and H. F. Kotze Antithrombotic Effect of Platelet Glycoprotein Ib-Blocking Monoclonal Antibody Fab Fragments in Nonhuman Primates Arterioscler Thromb Vasc Biol, May 1, 2000; 20(5): 1347 - 1353. [Abstract] [Full Text] [PDF]

				K. Eto, T. Isshiki, H. Yamamoto, S. Takeshita, M. Ochiai, N. Yokoyama, R. Yoshimoto, Y. Ikeda, and T. Sato AJvW-2, an Anti-vWF Monoclonal Antibody, Inhibits Enhanced Platelet Aggregation Induced by High Shear Stress in Platelet-Rich Plasma From Patients With Acute Coronary Syndromes Arterioscler Thromb Vasc Biol, April 1, 1999; 19(4): 877 - 882. [Abstract] [Full Text] [PDF]

				J. Schulte am Esch II, M. A. Cruz, J. B. Siegel, J. Anrather, and S. C. Robson Activation of Human Platelets by the Membrane-Expressed A1 Domain of von Willebrand Factor Blood, December 1, 1997; 90(11): 4425 - 4437. [Abstract] [Full Text] [PDF]

				P. Andre, P. Hainaud, C. Bal dit Sollier, L. I. Garfinkel, J. P. Caen, and L. O. Drouet Relative Involvement of GPIb/IX-vWF Axis and GPIIb/IIIa in Thrombus Growth at High Shear Rates in the Guinea Pig Arterioscler Thromb Vasc Biol, May 1, 1997; 17(5): 919 - 924. [Abstract] [Full Text]

				P. K. Shah New Antithrombotic Drugs for Coronary Artery Disease Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 1996; 1(2): 165 - 176. [PDF]